CORE--SEPARATING NORMAL/LEUKEMIC CELLS IN MARROW/PERIPHERAL BLOOD IN AML PATIENTS

骨髓髓系细胞可以分成几类，它们表现出 携带形态的不同自我更新能力 成熟度和不同免疫表型的特点。 自我更新的潜力越大，频率就越低 这些细胞。荧光激活细胞分选(FACS)已被 用来培养早期髓系细胞群体，这些细胞是 富含表型CD34+CD38-Lin-Thy-1+(Lo)Rho(Lo)。 这些细胞被证明具有很高的增殖潜力。 部分AML细胞Thy-1+lo表型为阴性。这个 T(15；17)AML亚群CD34+CD33阴性 细胞。这一数据向一些人表明，预后良好的AML 亚群不会穿透到早期的髓鞘间， 而预后较差的子集可能包含具有 免疫表型CD34+CD38-CD33-Thy-1(Lo)。我们将对此进行测试 利用高速FACS细胞分选开发假说 具有CD34+CD38-的AML患者细胞群 Lin-Thy+1(Lo)Rho(Lo)表型，然后用FISH和PCR检测 寻找急性髓系白血病细胞的证据。

Marrow myeloid cells can be separated into classes which exhibit different self-renewal capabilities carrying morphological features with respect to maturation and differing immunophenotype. The greater the self-renewal potential, the less frequent are these cells. Fluorescent activated cell sorting (FACS) has been used to develop populations of early myeloid cells which are enriched with the phenotype CD34+CD38-Lin-Thy-1 +(lo)Rho(lo). These cells have been shown to have high proliferative potential. Some AML cells show negativity for the Thy-1+lo phenotype. The t(15; 17) AML subset has been shown to be negative for CD34+CD33- cells. This data has suggested to some that the good prognosis AML subsets do not penetrate into the early myeloid compartment, whereas the poor prognostic subsets may contain cells with the immunophenotype CD34+CD38-CD33-Thy-1(lo). We will test this hypothesis by using high speed FACS cell sorting to develop populations of cells from AML patients which have the CD34+CD38- Lin-Thy+1(lo)Rho(lo) phenotype and then test this by FISH and PCR for evidence of AML cells.